GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Merck Co. Inc.
Merck & Co.'s stock price is driven by its success in developing breakthrough drugs. Its key growth driver is the cancer immunotherapy drug Keytruda, one of the world's best-selling. The chart shows how a single blockbuster can transform the value of a pharmaceutical company.
Share prices of companies in the market segment - Pharma holding
Merck is a global pharmaceutical giant whose key segments are oncology, led by the blockbuster Keytruda, and vaccines. We classify it as part of the Pharma Holdings sector, and the chart below shows the overall performance of the entire industry of large drugmakers.
Broad Market Index - GURU.Markets
Merck & Co. is one of the world's leading pharmaceutical companies, with a strong portfolio of oncology and vaccines. Its significant market capitalization earns it a prominent place in the GURU.Markets index. The chart below represents the entire market. See how Merck shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
MRK - Daily change in the company's share price Merck Co. Inc.
Daily price changes for Merck, a leading pharmaceutical company, reflect its response to clinical trial results and strategic decisions. While the graph of these fluctuations is unspectacular, they are an important component of formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma holding
Merck & Co., Inc. is one of the world's leading pharmaceutical companies. This chart reflects the average daily volatility of the entire industry. For investors in Merck, it serves as a benchmark to assess whether its successful oncology portfolio (Keytruda) makes the company more or less stable than its diversified peers.
Daily change in the price of a broad market stock, index - GURU.Markets
Merck & Co. is one of the oldest and largest pharmaceutical companies in the world. The pharmaceutical sector can be defensive, but breakthroughs and setbacks in drug development create their own volatility. The chart below shows overall market dynamics, allowing you to assess how Merck fits into the global landscape.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Merck Co. Inc.
Merck & Co. has demonstrated strong growth over the past year, driven by its blockbuster oncology drug Keytruda and advances in vaccine development. The stock performance shown in the chart reflects the company's dominant position in immuno-oncology and the strength of its R&D.
Annual dynamics of market capitalization of the market segment - Pharma holding
Merck & Co., Inc. is a leading global pharmaceutical company, whose success is largely due to its oncology blockbuster, Keytruda. Reliance on a single mega-drug creates risks, but its dominance ensures the company's growth, often outpacing the industry average. The chart below clearly demonstrates this.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Merck & Co. is a leading pharmaceutical company, fueled by blockbusters like the oncology drug Keytruda. Its performance is less dependent on the economy and more dependent on research success and patent protection. This makes its shares attractive to investors seeking growth unrelated to general market cycles.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Merck Co. Inc.
Merck & Co.'s value is determined by its success in drug development and commercialization. Monthly fluctuations on the chart are closely linked to news about clinical trials, particularly the oncology blockbuster Keytruda, as well as regulatory decisions and sales data for key drugs.
Monthly dynamics of market capitalization of the market segment - Pharma holding
What you see here is the dynamics of the entire pharmaceutical sector, of which Merck is a pillar. Its movements reflect both general trends and the success of individual blockbusters. This is the backdrop against which Merck, thanks to its oncology drug Keytruda, has demonstrated confident growth.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
This chart reflects overall market sentiment. For Merck, a major pharmaceutical company, it's the backdrop. Its movements are typically less volatile than the market, reflecting the defensive nature of its business, supported by the success of its oncology blockbuster Keytruda.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Merck Co. Inc.
Merck & Co., one of the world's leading drugmakers, sees its shares fluctuate weekly, driven by news of the blockbuster drug Keytruda, the results of new drug trials, and patent disputes. The chart reflects investor expectations for the company's future growth after patents on key products expire.
Weekly dynamics of market capitalization of the market segment - Pharma holding
Merck & Co., thanks to its blockbuster drug Keytruda, often outperforms the entire pharmaceutical sector. While the industry may show modest growth, news of Keytruda's success can push Merck shares higher. The chart shows the magnitude of this "blockbuster effect" and how it differentiates the company from its competitors.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Merck & Co. is one of the world's leading pharmaceutical companies. The Big Pharma sector is traditionally considered a defensive sector due to stable demand for drugs. Compare Merck's weekly performance with the market to assess whether its shares are truly mitigating overall market volatility.
Market capitalization of the company, segment and market as a whole
MRK - Market capitalization of the company Merck Co. Inc.
Merck & Co.'s market capitalization chart reflects how the market views the company's success in immuno-oncology. A significant portion of its value is built on the blockbuster drug Keytruda. The chart's dynamics show how investors are reacting to data on the drug's expanding use and how they view the company's ability to diversify revenues with other drugs.
MRK - Share of the company's market capitalization Merck Co. Inc. within the market segment - Pharma holding
Merck & Co. is a pillar of the global pharmaceutical industry. Its significant market share is driven by the success of blockbusters, particularly in oncology, such as Keytruda. The company's market capitalization reflects its leadership in the development of life-saving drugs.
Market capitalization of the market segment - Pharma holding
Here's a chart reflecting the trillion-dollar value of global pharmaceuticals. Merck & Co. is one of its pillars, with a history of great discoveries and a strong position in oncology, particularly with the blockbuster Keytruda. The dynamics of this market are driven by scientific breakthroughs, and Merck continues to play a leading role in this process.
Market capitalization of all companies included in a broad market index - GURU.Markets
Merck & Co. is one of the world's oldest pharmaceutical companies, having created numerous breakthrough drugs. Its market value is based on its patent portfolio and ongoing research. The chart below shows the global market share of research-based pharmaceuticals.
Book value capitalization of the company, segment and market as a whole
MRK - Book value capitalization of the company Merck Co. Inc.
Merck & Co.'s foundation is its robust R&D centers, particularly in oncology and vaccines, and its global manufacturing network. Its book value reflects the resources needed to create blockbusters like Keytruda. The chart below tells the story of how scientific breakthroughs translate into patents and manufacturing assets that strengthen the company.
MRK - Share of the company's book capitalization Merck Co. Inc. within the market segment - Pharma holding
Novo Nordisk, a leader in diabetes treatment, is bolstering its position with massive investments in manufacturing. The chart shows the company's share of physical pharmaceutical assets, particularly in insulin and new drug manufacturing plants. This reflects its ability to meet growing global demand.
Market segment balance sheet capitalization - Pharma holding
Pharmaceuticals, as the chart shows, is a capital-intensive industry. Merck & Co., one of its pillars, is a prime example. The company invests billions in both scientific research (R&D) and the construction and maintenance of a global network of drug manufacturing plants.
Book value of all companies included in the broad market index - GURU.Markets
Merck & Co. is a pharmaceutical industry veteran with over a century of history. Its solid balance sheet value stems from a global network of manufacturing facilities and advanced laboratories, as well as a valuable portfolio of patents for blockbusters, such as the cancer immunotherapy drug Keytruda.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Merck Co. Inc.
Merck & Co. is a pharmaceutical giant, and the market values it significantly above its tangible assets. This premium is driven by the strength of its oncology blockbuster Keytruda and other successful drugs, as well as confidence in its scientific potential.
Market to book capitalization ratio in a market segment - Pharma holding
Merck & Co. is a global pharmaceutical company whose success depends largely on its oncology drug Keytruda. The market values both the current revenue from this blockbuster and the company's ability to find new sources of growth. This chart shows how expectations for its product portfolio and R&D create a market value significantly exceeding its tangible assets.
Market to book capitalization ratio for the market as a whole
Merck & Co. is one of the world's leading pharmaceutical companies, whose success depends largely on its oncology blockbuster Keytruda. This chart reflects the average market valuation of the company. Against this backdrop, Merck's premium reflects how investors value its current revenues, but also closely monitor its portfolio diversification and future developments.
Debts of the company, segment and market as a whole
MRK - Company debts Merck Co. Inc.
For Merck & Co., a pillar of the pharmaceutical industry, debt is a tool for maintaining long-term competitiveness. The company uses debt to finance multibillion-dollar R&D programs, particularly in oncology (Keytruda), and for strategic transactions. This chart shows how its financial structure supports a research-intensive business.
Market segment debts - Pharma holding
Merck & Co. is a global pharmaceutical company whose success depends on a constant stream of new drugs. Investments in R&D and acquisitions of biotech startups are key to future growth. Debt is used to finance these strategic initiatives, allowing the company to remain competitive. This chart shows how Merck manages its finances to support innovation.
Market debt in general
Merck & Co. is one of the world's leading pharmaceutical companies, known for its oncology developments, particularly Keytruda. Maintaining this leadership position requires significant and risky investments in R&D. This chart shows the overall picture of its debt obligations, allowing us to assess how Merck finances its innovations compared to the rest of the market.
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Merck Co. Inc.
Merck & Co. is a pharmaceutical giant whose success is largely due to its immuno-oncology blockbuster Keytruda. This chart shows how the company uses its capital. Debt can be used to acquire new technologies and drugs, diversify revenue, and prepare for the future loss of exclusivity on its key drugs.
Market segment debt to market segment book capitalization - Pharma holding
Merck & Co. is a global pharmaceutical company whose revenue depends largely on the success of several key blockbuster drugs. Investments in R&D to discover new drugs are critical. This chart shows how the company funds this research, comparing its debt load to the overall market capitalization of the pharmaceutical industry.
Debt to book value of all companies in the market
Merck & Co. is a global pharmaceutical company with significant financial resources for R&D and strategic acquisitions. This chart compares its conservative financial policy with the overall market environment. It shows how this giant's debt load compares to the average leverage of all publicly traded companies.
P/E of the company, segment and market as a whole
P/E - Merck Co. Inc.
This chart shows the market valuation of Merck & Co., a pharmaceutical giant whose success depends heavily on its oncology blockbuster Keytruda. The company's P/E is heavily tied to the drug's sales forecasts and investor confidence in Merck's research labs' ability to find new growth opportunities.
P/E of the market segment - Pharma holding
Merck & Co. is a global pharmaceutical company whose flagship product is the immuno-oncology blockbuster Keytruda. Dependence on a single drug is a key concern for investors. This chart shows the average valuation for the pharmaceutical industry, which helps assess the extent to which the risks associated with Keytruda's future are reflected in Merck's current valuation.
P/E of the market as a whole
Merck & Co. is a global pharmaceutical company known for its oncology developments, particularly Keytruda. Its valuation depends primarily on the success of clinical trials and the maintenance of patent protection for key drugs. While this chart shows general market trends, Merck is much more interested in news from the worlds of science and medicine.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Merck Co. Inc.
Merck & Co. is one of the world's leading pharmaceutical companies, whose valuation is largely determined by the success of its oncology blockbuster Keytruda. This chart reflects investor expectations regarding the future of this drug and the company's ability to develop new sources of growth to offset the future loss of patent protection for its key drugs.
%20P%2FE%20Merck%20Co.%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Merck-Co.-Inc.&v=1772600923574 "Chart of the company's future (projected) P/E Merck Co. Inc.")
Future (projected) P/E of the market segment - Pharma holding
Merck & Co. is a global pharmaceutical company whose flagship product is the cancer immunotherapy drug Keytruda. The company's success depends heavily on this blockbuster. This chart reflects the market's valuation of its product portfolio. Comparison with the sector reveals whether investors believe in its ability to find new growth drivers.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-holding&v=1772600923732 "Future (projected) P/E graph of the market segment - Pharma holding")
Future (projected) P/E of the market as a whole
Merck & Co. is one of the world's leading pharmaceutical companies, whose success is largely due to its oncology blockbuster, Keytruda. For Merck, as for the entire industry, clinical trial results are key. However, the overall market environment, as shown in this chart, influences the company's valuation and its ability to pursue M&A deals.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772600923807 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Merck Co. Inc.
Merck & Co., Inc. is a global pharmaceutical company whose profits depend heavily on the success of its oncology drug Keytruda and vaccines. This chart shows how sales of these key products and clinical trial results for new drugs shape the company's financial health as it searches for its next blockbusters.
Profit of companies in the market segment - Pharma holding
Merck & Co. is a leading global pharmaceutical company, whose success is largely due to its immuno-oncology blockbuster, Keytruda. This example demonstrates how a single breakthrough drug can radically transform a company's financial position and set a new standard of care, influencing profitability across the entire pharmaceutical market.
Overall market profit
Merck & Co. is one of the world's largest pharmaceutical companies, renowned for its developments in oncology, vaccines, and infectious disease treatments. Its blockbusters, such as its cancer immunotherapy drug, generate billions of dollars in revenue. Merck's success demonstrates how scientific breakthroughs can create enormous economic value and improve the quality of life for millions of people.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Merck Co. Inc.
Merck & Co. is a global pharmaceutical company whose success is largely driven by its oncology drug Keytruda. This chart reflects expectations for the continued sales growth of this blockbuster, as well as the prospects for other products in the portfolio and developments in the R&D pipeline.
%20profit%20of%20the%20company%20Merck%20Co.%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Merck-Co.-Inc.&v=1772600924174 "Graph of future (projected) profit of the company Merck Co. Inc.")
Future (predicted) profit of companies in the market segment - Pharma holding
Merck & Co. is one of the world's leading pharmaceutical companies, whose success is largely due to its oncology blockbuster Keytruda. This chart reflects profitability forecasts for the entire pharmaceutical industry. It allows you to compare Merck's prospects, dependent on the life cycle of its key drugs, with analysts' overall expectations for the sector.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-holding&v=1772600924273 "Graph of future (predicted) profits of companies in a market segment - Pharma holding")
Future (predicted) profit of the market as a whole
Merck & Co.'s profit forecast is largely dependent on sales of its oncology blockbuster, Keytruda. This chart reflects expectations for the drug's continued growth and the company's ability to develop other promising drugs, including vaccines. The forecast is sensitive to news about clinical trials and the competitive environment.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772600924329 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Merck Co. Inc.
Merck & Co. is a global pharmaceutical company whose revenue is heavily dependent on the success of its oncology drug Keytruda. This chart shows how the market values its sales given its reliance on a single blockbuster. The market multiple reflects investor confidence in the company's portfolio and its ability to develop new drugs.
P/S market segment - Pharma holding
Merck & Co. is one of the world's leading pharmaceutical companies, known for its oncology blockbuster Keytruda and a strong vaccine portfolio. This metric reflects the average revenue estimate in the pharmaceutical industry and helps understand the premium investors are willing to pay for Merck's leadership in immuno-oncology and its scientific developments.
P/S of the market as a whole
Merck & Co. is a global pharmaceutical company whose revenue is largely dependent on the success of its oncology drug Keytruda. The company is actively pursuing new sources of growth. This chart, which displays Merck's average revenue estimates, helps understand the market's concerns about its reliance on a single product and its view of the company's future development prospects.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Merck Co. Inc.
Merck & Co. is one of the world's leading pharmaceutical companies, whose success owes much to its oncology blockbuster, Keytruda. The company's future revenue estimates are heavily dependent on sales forecasts for this drug and its successor developments. This chart shows how confident investors are in Merck's R&D pipeline and its ability to grow beyond Keytruda.
%20P%2FS%20Merck%20Co.%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Merck-Co.-Inc.&v=1772600924674 "The graph of the company's future (projected) P/S Merck Co. Inc.")
Future (projected) P/S of the market segment - Pharma holding
Merck & Co. is a global pharmaceutical company whose flagship product is the immuno-oncology blockbuster Keytruda. This chart shows how the market views its reliance on a single drug. Do investors believe the company can develop new revenue streams before Keytruda faces patent collapse?
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20holding&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-holding&v=1772600924790 "Future (projected) P/S market segment graph - Pharma holding")
Future (projected) P/S of the market as a whole
Merck & Co. is a leading pharmaceutical company whose revenues depend largely on the success of its blockbuster oncology drug, Keytruda. Merck's ability to grow sales and develop new drugs supports investor optimism across the sector. This contributes to the overall positive growth expectations illustrated by this chart.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772600924947 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Merck Co. Inc.
Merck & Co. is one of the world's leading pharmaceutical companies, renowned for its oncology developments, particularly the blockbuster Keytruda. This chart demonstrates the commercial success of its drug portfolio and its ability to bring new, in-demand drugs to market for the treatment of serious diseases.
Sales of companies in the market segment - Pharma holding
Merck & Co. is one of the world's leading pharmaceutical companies, with strong positions in oncology, vaccines, and animal health. Its future depends on the success of key drugs like Keytruda and new developments. This chart shows overall pharmaceutical sales, demonstrating the scale of the market in which Merck competes with other giants through scientific innovation.
Overall market sales
Merck & Co. is one of the world's leading pharmaceutical companies, known for its blockbusters in oncology and vaccines. The company's growth is driven by innovation in research. This overall economic activity curve is important for Merck because it impacts healthcare budgets and the public's ability to pay, which affects the affordability of its medicines.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Merck Co. Inc.
Merck & Co. is a major pharmaceutical company whose growth is largely driven by the success of its cancer immunotherapy drug Keytruda. The company's future revenue depends on the expansion of this blockbuster drug and the launch of new promising drugs. This chart reflects analysts' forecasts for Keytruda's peak sales and the potential of other drugs in development.
%20sales%20of%20the%20company%20Merck%20Co.%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Merck-Co.-Inc.&v=1772600925369 "Schedule of future (projected) sales of the company Merck Co. Inc.")
Future (projected) sales of companies in the market segment - Pharma holding
Merck & Co., Inc. is a leading global pharmaceutical company, known for its oncology drugs (Keytruda), vaccines, and veterinary products. This chart reflects the aggregate sales forecast for the entire pharmaceutical sector. It provides insight into overall expectations for healthcare spending growth, which is important context for assessing Merck's business.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-holding&v=1772600925460 "Schedule of future (projected) sales of companies in the market segment - Pharma holding")
Future (projected) sales of the market as a whole
Merck & Co. is one of the world's leading pharmaceutical companies. Demand for its key drugs and vaccines is generally resilient to economic fluctuations. However, the overall economic situation, reflected in this chart, affects the solvency of healthcare systems and government budgets. This, in turn, determines pricing opportunities and the introduction of new, expensive drugs.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772600925513 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Merck Co. Inc.
Merck & Co. is one of the world's leading pharmaceutical companies, known for its oncology developments, particularly Keytruda. This chart clearly demonstrates how a single, highly successful blockbuster drug can generate enormous financial returns and propel the entire company forward. The dynamics here represent the success story of a single drug.
Market segment marginality - Pharma holding
Merck & Co. is one of the world's leading pharmaceutical companies, whose success is largely driven by its blockbuster oncology drug Keytruda. A focus on innovative drugs and a strong research pipeline are key to its future profitability. The data demonstrates how the company's highly successful proprietary products provide outstanding profitability.
Market marginality as a whole
Merck & Co. is a global pharmaceutical company whose profitability is largely determined by the success of blockbusters like the cancer immunotherapy drug Keytruda. This chart shows overall profitability. Using it, Merck illustrates a model in which a single, highly successful product can generate colossal profits, helping to fund research into new drugs.
Employees in the company, segment and market as a whole
Number of employees in the company Merck Co. Inc.
Merck & Co. is one of the world's leading pharmaceutical companies, known for its blockbuster oncology (Keytruda) and vaccines. This chart shows the size of the team behind research and global sales. The growth in headcount is directly related to the expansion of indications for key drugs and investments in new drug development.
Share of the company's employees Merck Co. Inc. within the market segment - Pharma holding
This chart demonstrates Merck & Co.'s importance as a pillar of the global pharmaceutical industry. Its significant share of employees in the sector reflects its massive investment in research and development, particularly in oncology and vaccines. These are the scientific and commercial staff behind blockbusters like Keytruda.
Number of employees in the market segment - Pharma holding
Merck & Co. is one of the world's oldest and largest pharmaceutical companies, renowned for its vaccines and blockbuster drugs. Its success is based on a strong scientific foundation and thousands of researchers. This chart illustrates the importance of human capital in the pharmaceutical industry, where Merck has been a magnet for top scientists for decades.
Number of employees in the market as a whole
Merck & Co. is one of the world's oldest pharmaceutical companies, known today primarily for its oncology blockbuster, Keytruda, and vaccines (Gardasil). This graph of total employment reflects the state of payers. Merck's success depends on the ability of the healthcare system (insurers and governments), financed by contributions from the working population, to pay for its expensive and effective drugs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Merck Co. Inc. (MRK)
Merck & Co. is one of the world's leading pharmaceutical companies. Its future depends on discoveries in its laboratories. A high value for this metric directly reflects how investors evaluate its patent portfolio and the potential of its drug development, where the intellectual capital of each scientist is of immense value.
%20of%20the%20company%20Merck%20Co.%20Inc.%20(MRK)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Merck-Co.-Inc.-MRK&v=1772600925989 "Chart of market capitalization per employee (in thousands of dollars) of the company Merck Co. Inc. (MRK)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma holding
Merck & Co. is a blockbuster story. The company's success depends largely on its super-drug, Keytruda. The company's entire value lies in its R&D labs. This metric is a clear reflection of this fact: it shows the gigantic market capitalization the market attributes to each employee, expecting them to produce the next Keytruda.
%20by%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-holding&v=1772600926007 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma holding")
Market capitalization per employee (in thousands of dollars) for the overall market
Merck & Co. is one of the world's leading pharmaceutical companies, known for its oncology developments (Keytruda). This chart illustrates how the market values its patented drug portfolio. Its high market capitalization per employee is the result of its focus on R&D and the creation of products with enormous market value.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772600926051 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Merck Co. Inc. (MRK)
Merck & Co. is an American pharmaceutical giant whose profits are largely due to the blockbuster drug Keytruda (oncology). This chart is a classic pharmaceutical success story. It shows how a single breakthrough, patent-protected drug can generate colossal profits, ensuring the highest return on every employee, from lab technician to marketer.
%20Chart%20Merck%20Co.%20Inc.%20(MRK)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Merck-Co.-Inc.-MRK&v=1772600926083 "Company Profit Per Employee (in thousands of dollars) Chart Merck Co. Inc. (MRK)")
Profit per employee (in thousands of dollars) in the market segment - Pharma holding
Merck & Co. is an American pharmaceutical giant. This chart shows the average for the entire pharmaceutical industry. This sector is a "blockbuster business." Average employee profitability is high, as a single successful drug patent (like Keytruda) can generate billions, more than covering R&D costs and ensuring high profits per scientist.
%20in%20the%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-holding&v=1772600926112 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma holding")
Profit per employee (in thousands of dollars) for the market as a whole
Merck & Co. is one of the world's oldest pharmaceutical companies, known for its vaccines and drugs, such as the cancer immunotherapy drug Keytruda. Its success is directly dependent on scientific breakthroughs. This metric clearly illustrates how a single blockbuster, created by a team of researchers, can generate billions in revenue and high profit per employee.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772600926155 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Merck Co. Inc. (MRK)
Merck & Co. is one of the world's oldest pharmaceutical companies, the creator of blockbusters like Keytruda. This chart is a classic example of pharmaceutical productivity. The company's exceptional revenue per employee is the result of years of research, leading to a single, highly profitable patent that justifies all costs.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Merck-Co.-Inc.-MRK&v=1772600926185 "Sales chart per company employee Merck Co. Inc. (MRK)")
Sales per employee in the market segment - Pharma holding
Merck & Co. is a leading pharmaceutical company known for its oncology blockbuster Keytruda and vaccines. This chart shows the average revenue per employee in the segment. It demonstrates how effectively Merck's R&D and commercial divisions generate revenue based on their key drugs compared to other Big Pharma companies.
Sales per employee for the market as a whole
Merck & Co. is another "big pharma" giant whose fate largely depends on the success of a single drug—the blockbuster Keytruda (oncology). This chart vividly illustrates the economics of pharmaceuticals: investments in R&D lead to the creation of a patent, which then generates billions of dollars, ensuring very high profits for the entire company's workforce.
Short shares by company, segment and market as a whole
Shares shorted by company Merck Co. Inc. (MRK)
Merck & Co. is a pharmaceutical giant whose profits depend heavily on the blockbuster Keytruda (immuno-oncology). This chart shows the bets of those who fear a "patent cliff." The bears are betting that the company will be unable to find an adequate replacement for Keytruda after its patent expires, leading to a sharp decline in revenue.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Merck-Co.-Inc.-MRK&v=1772600926306 "Short Shares Chart for the Company Merck Co. Inc. (MRK)")
Shares shorted by market segment - Pharma holding
Merck & Co. is a pillar of "big pharma," whose stability depends largely on the blockbuster Keytruda (oncology) and vaccines. This chart shows the overall sentiment toward the sector. It reflects investor concerns about "patent cliffs" (loss of exclusivity) or increased government regulation of drug prices across the industry.
Shares shorted by the overall market
Merck & Co. is a pharmaceutical giant whose stability rests largely on the blockbuster Keytruda, a cancer immunotherapy drug. Demand for life-saving drugs is acyclical. This chart measures overall fear. During periods of market panic, investors seek "safety" in stocks with predictable cash flow, and Merck is a classic choice.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Merck Co. Inc. (MRK)
Merck & Co., the pharmaceutical giant, is heavily dependent on the success of its blockbuster drug Keytruda. This indicator, above 70, may reflect Keytruda's continued growth or R&D success. Oversold levels (<30) are often associated with concerns about future competition for Keytruda or failures in new drug development.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Merck-Co.-Inc.-MRK&v=1772600926373 "RSI 14 indicator chart for the company's stock Merck Co. Inc. (MRK)")
RSI 14 Market Segment - Pharma holding
Merck (MRK) is a pillar of Big Pharma, whose success rests on the oncology blockbuster Keytruda and the Gardasil vaccine. The challenge is what will happen after the Keytruda patent collapse. This metric measures the "temperature" of the entire pharmaceutical sector. It helps us understand whether Merck is overheated due to its strength in oncology, or whether the entire sector is overbought.
RSI 14 for the overall market
Merck & Co. is a global pharmaceutical leader whose flagship product is the oncology blockbuster Keytruda. The company is also strong in vaccines. This indicator measures the overall market backdrop, showing when investors in general (in panic) are seeking refuge in "defensive" healthcare stocks or (in euphoria) are ignoring them in favor of hotter sectors.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast MRK (Merck Co. Inc.)
This chart shows the collective opinion on Merck. When setting their price targets, analysts focus almost exclusively on the "blockbuster" Keytruda (oncology). Their forecasts are an attempt to estimate how long Keytruda will dominate and what will happen when it loses patent protection. The price target is a bet that Merck's R&D pipeline will be able to find the "next Keytruda."
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-MRK-Merck-Co.-Inc.&v=1772600926471 "A chart showing analyst consensus forecasts for the expected stock price. MRK (Merck Co. Inc.)")
The difference between the consensus estimate and the actual stock price MRK (Merck Co. Inc.)
Merck & Co., Inc. is a global pharmaceutical company whose growth is largely driven by its immuno-oncology blockbuster, Keytruda. This chart shows the gap between the consensus estimate and the price. It illustrates whether analysts believe Merck's R&D pipeline can offset the future loss of Keytruda's exclusivity, seeing growth potential in new developments.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-MRK-Merck-Co.-Inc.&v=1772600926491 "A chart showing the difference between the consensus forecast and the actual stock price. MRK (Merck Co. Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma holding
Merck & Co. is a pharmaceutical giant whose growth is largely driven by its oncology blockbuster Keytruda. The company is actively pursuing new sources of revenue. This chart reflects analysts' general expectations for the entire pharmaceutical sector. It shows whether experts believe in the success of new drugs in the industry or fear dependence on older hits.
Analysts' consensus forecast for the overall market share price
Merck is a big pharma giant, strong in oncology (Keytruda) and vaccines. Healthcare is a defensive sector. This chart shows the overall consensus forecast for the market. It helps us understand what investors value more: defense (as the chart declines) or growth. During periods of panic, investors often flee to stable dividend stocks like Merck.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Merck Co. Inc.
Merck & Co. is a global pharmaceutical giant whose financial health relies heavily on a single drug—the immuno-oncology leader Keytruda. This chart reflects this focus. It demonstrates the market's confidence in Keytruda's continued dominance while simultaneously assessing the urgency with which their R&D team must find the next blockbuster.
AKIMA Market Segment Index - Pharma holding
Merck & Co. is a global pharmaceutical company whose flagship product is the blockbuster Keytruda, which has revolutionized cancer treatment. This comprehensive index evaluates R&D. The chart shows the average value for the segment. It helps understand the extent to which Keytruda's dominance and Merck's R&D pipeline allow it to outperform the average pharmaceutical company in this metric.
The AKIM Index for the overall market
Merck & Co. is a global pharmaceutical company whose flagship product is Keytruda, a blockbuster in immuno-oncology. The company also has strong positions in vaccines and veterinary products. This chart, showing the market average, is important for context. It allows us to assess how Merck, whose success depends on R&D and patent exclusivity, compares to the overall macroeconomic trends affecting markets.
